Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06914908 · ClinicalTrials.gov registry record · Phase 2

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

A Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi.

Recruiting
Registry status
Phase 2
Development phase
64
Enrollment target
20
Study locations

NCT06914908: Recruiting Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi.

NCT06914908 is a Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps that is actively recruiting participants, run by Sanofi. The registered enrollment target is 64 participants, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06914908, a Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps, is actively recruiting participants, sponsored by Sanofi.

RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
20
Study locations

Study Summary

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.

Conditions Studied

Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • DRUG Mometasone furoate nasal spray (MFNS)
  • DRUG lunsekimig

Study Locations (20)

Other

  • Investigational Site Number : 0320001 - Buenos Aires
  • Investigational Site Number : 0320003 - Mendoza
  • Investigational Site Number : 0560002 - Ghent
  • Investigational Site Number : 0560001 - Leuven
  • Investigational Site Number : 1000001 - Sofia
  • Investigational Site Number : 8260003 - Manchester
  • Investigational Site Number : 8260001 - Newcastle upon Tyne

Texas

  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 - Bellaire
  • Pharmaceutical Research & Consulting- Site Number : 8400004 - Dallas
  • ENT Associates of Texas - McKinne- Site Number : 8400014 - McKinney
  • Alamo ENT Associates- Site Number : 8400001 - San Antonio

California

  • Modena Allergy + Asthma- Site Number : 8400005 - La Jolla

Idaho

  • Treasure Valley Medical Research- Site Number : 8400002 - Boise

Oklahoma

  • Essential Medical Research- Site Number : 8400020 - Tulsa

Santa Fe Province

  • Investigational Site Number : 0320002 - Rosario

Greater Poland Voivodeship

  • Investigational Site Number : 6160004 - Poznan

Lesser Poland Voivodeship

  • Investigational Site Number : 6160002 - Krakow

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2025-05-12
Est. Completion 2031-01-29
Phase Phase 2
Sanofi

713 total trials

What NCT06914908 shows while recruiting

NCT06914908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 2 interventions - of which Mometasone furoate nasal spray (MFNS) is the first listed.

NCT06914908 names 20 study sites across 11 states, led by Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06914908 about?

NCT06914908 is a clinical study titled "Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study". This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study dura...

What is the current status of trial NCT06914908?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2025-05-12. Estimated completion is 2031-01-29.

What conditions does trial NCT06914908 study?

This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.

What interventions are being tested in trial NCT06914908?

The interventions under investigation include: Mometasone furoate nasal spray (MFNS) (DRUG), lunsekimig (DRUG).

Who is sponsoring clinical trial NCT06914908?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06914908 being conducted?

This trial has 20 study locations across California, Idaho, Oklahoma, Texas, Santa Fe Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Rhinosinusitis With Nasal Polyps

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06914908's enrollment target sits among peer trials

64 7th of 11 higher than 5 of 11 other Chronic Rhinosinusitis With Nasal Polyps trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Rhinosinusitis With Nasal Polyps trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06914908

Source: ClinicalTrials.gov NCT06914908, the US trial registry maintained by the National Library of Medicine. NCT06914908 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.